Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Identification of genetic and functional biomarkers that predict PPAR-gamma-associated fluid retention and oedema
2008-001634-28Phase 4Terminated
- Sponsor
- University of Dundee
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pioglitazone in type 2 diabetes mellitus (T2DM), sponsored by University of Dundee. Primary endpoints: Influence of Pro12Ala genotype on body water and oedema formation and Mechanisms and biomarkers of increased fluid retention risk. Started Aug 2008; status: terminated.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-001634-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001634-28.